Version 1
: Received: 4 August 2023 / Approved: 7 August 2023 / Online: 8 August 2023 (09:18:51 CEST)
Version 2
: Received: 29 September 2023 / Approved: 30 September 2023 / Online: 3 October 2023 (03:15:10 CEST)
Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7. https://doi.org/10.3390/vaccines12010007
Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7. https://doi.org/10.3390/vaccines12010007
Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7. https://doi.org/10.3390/vaccines12010007
Swamy, K. Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy—A Translational Model. Vaccines 2024, 12, 7. https://doi.org/10.3390/vaccines12010007
Abstract
Immunotherapy alone or in combination is expected to play a huge role in managing malignancies soon. Presently its benefit extends to about 12% to 20% of patients, in the background of possible recurrence eventually and the toxicities in the patients who don’t respond. Stereotactic boy radiotherapy (SBRT) is a powerful non-invasive immunological tool capable of eliminating the indexed lesions and as dependable in situ therapeutic vaccine production to activate short and long-term memory immune lymphocytes. This happens with the ability of stereotactic body radiotherapy (SBRT) to generate tumor-specific neoantigens and epitopes, which enhance the potency of antigen-presenting cell invoking and restoring the ability of tumor-infiltrating lymphocytes resulting in cancer cell lysis. This cell lysis, in turn, can generate further neoantigens and epitopes, imparting a virtuous cycle that is the hallmark of vaccines. Additionally, SBRT can synergistically enhance the other in situ vaccination strategies with or without in vitro vaccines, nanomedicines, etc., making it a primary tool for sensitizing even the “cold” tumors for immunotherapy. These in situ vaccination capabilities of SBRT in larger perspectives are already proposed by the present author and are published elsewhere. The current hypotheses / theoretical review of the literature-based article primarily focuses on the critical aspects of in situ vaccination generation of SBRT when used in cyclical or intermittent multistep endothelial-sparing single dose schedules in metastatic or recurrent cancer settings.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter:
Commenter's Conflict of Interests: I am one of the author